Next Article in Journal
The Impact of Sport Training on Oral Health in Athletes
Next Article in Special Issue
Identifying Risk Factors Affecting the Usage of Digital and Social Media: A Preliminary Qualitative Study in the Dental Profession and Dental Education
Previous Article in Journal
Dentinogenesis Imperfecta and Caries in Osteogenesis Imperfecta among Vietnamese Children
Previous Article in Special Issue
Maintenance of Dental Records and Forensic Odontology Awareness: A Survey of Croatian Dentists with Implications for Dental Education
Case Report

Epi-Mucosa Fixation and Autologous Platelet-Rich Fibrin Treatment in Medication-Related Osteonecrosis of the Jaw

1
Unit of Maxillofacial Surgery, Department of Medicine and Surgery, University of Salerno, 84084 Fisciano, Italy
2
Department of Radiology, University of Mississippi Medical Center, Jackson, MS 39216, USA
3
Department of Biomolecular Sciences, Maxillofacial Surgery, University of Mississippi, Jackson, MS 39216, USA
*
Authors to whom correspondence should be addressed.
Academic Editors: Marco Tatullo and Božana Lončar Brzak
Received: 1 March 2021 / Revised: 21 April 2021 / Accepted: 29 April 2021 / Published: 30 April 2021
(This article belongs to the Special Issue Dental Education)
Medication-related osteonecrosis of the jaw (MRONJ) frequently affects patients after treatments with bisphosphonates or denosumab, especially with high doses in patients with bone osteoporosis, neoplastic metastases, or possibly anti-angiogenic treatment for cancer. The aim of this article was to show a new treatment planning for stage 2 and stage 3 MRONJ using platelet-rich fibrin (PRF) at the surgical field to enhance healing in association with a new epi-mucosal fixation technique to prevent or treat mandibular fracture. Two cases were treated by epi-mucosa fixation and autologous PRF use for prevention of mandibular fracture risks related to necrotic bone resection or a narrow fracture reduction. Both cases were successfully treated by this new technique of epi-mucosa fixation combined with autologous PRF and achieved good results and good quality of life. Ability to wear prosthesis with good mastication in the absence of side effect such as infection, plate and screw mobilization, pain, and other disabilities or extension of necrosis was reported. After surgical removal of necrotic bone, no infection was detected without any extension of the necrosis. View Full-Text
Keywords: medication-related osteonecrosis of the jaw; fracture; mandible; osteonecrosis; bisphosphonates medication-related osteonecrosis of the jaw; fracture; mandible; osteonecrosis; bisphosphonates
Show Figures

Figure 1

MDPI and ACS Style

Cortese, A.; Casarella, A.; Howard, C.M.; Claudio, P.P. Epi-Mucosa Fixation and Autologous Platelet-Rich Fibrin Treatment in Medication-Related Osteonecrosis of the Jaw. Dent. J. 2021, 9, 50. https://0-doi-org.brum.beds.ac.uk/10.3390/dj9050050

AMA Style

Cortese A, Casarella A, Howard CM, Claudio PP. Epi-Mucosa Fixation and Autologous Platelet-Rich Fibrin Treatment in Medication-Related Osteonecrosis of the Jaw. Dentistry Journal. 2021; 9(5):50. https://0-doi-org.brum.beds.ac.uk/10.3390/dj9050050

Chicago/Turabian Style

Cortese, Antonio, Antonio Casarella, Candace M. Howard, and Pier P. Claudio 2021. "Epi-Mucosa Fixation and Autologous Platelet-Rich Fibrin Treatment in Medication-Related Osteonecrosis of the Jaw" Dentistry Journal 9, no. 5: 50. https://0-doi-org.brum.beds.ac.uk/10.3390/dj9050050

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop